Houston Methodist Research Institute

Center for Clinical Studies, LTD. LLP (CCS) is a renowned clinical research center in Houston, Texas, founded by Dr. Stephen Tyring and Dr. Patricia Lee. With over 25 years of experience, CCS specializes in providing cutting-edge treatments for dermatological and infectious diseases, aiming to improve the lives of patients through quality clinical research and the discovery of new medicines. Recognized for their research excellence and ability to recruit patients, CCS collaborates with the pharmaceutical industry and government to conduct studies on various conditions, including acne, psoriasis, shingles, and more. Their commitment to advancing medical knowledge and offering innovative therapies has made them a trusted institution in the field of clinical research.Generated from the website

Moleculin Biotech, Inc, based in Houston, TX, is a cutting-edge biotechnology company focused on advancing a diverse pipeline of product candidates for the treatment of highly resistant cancers and viruses. Utilizing proprietary technologies and data, Moleculin is dedicated to developing innovative therapies, including a next-generation anthracycline, immune transcription modulators, STAT3 inhibitors, and metabolism glycosylation inhibitors. The company's priority development pipeline showcases their commitment to pioneering better treatments for challenging medical conditions, with a strong emphasis on delivering impactful solutions for patients facing complex diseases such as soft tissue sarcomas, acute myeloid leukemia, and other critical health challenges.Generated from the website

Cellula BioPharma, located in Pearland, TX, is pioneering a revolutionary CAR-T platform technology specifically designed for the treatment of solid tumors. Their innovative approach addresses the significant unmet need in the field, as current CAR-T therapies have shown limited effectiveness against solid tumors despite advancements in hematologic malignancies. The company has developed a unique Nucleotide Metabolic Reprogramed CAR (MRCA) that enhances the efficacy and safety of CAR-T cell therapy, validated through in vitro assays and various tumor mouse models. With a team of seasoned entrepreneurs, investigators, and physicians, Cellula BioPharma is positioned to overcome existing challenges in CAR-T therapy, particularly in promoting T cell persistence and combating immunosuppression in solid tumors. Generated from the website